“One of the biggest factors fueling the angst over drug prices in the U.S. is that some older medicines that should be sold cheaply as generics are still priced very high, often owing to a dwindling number of generic competitors and the rising cost of producing these drugs.”

American physician and investor

Scott Gottlieb is an American physician and investor. He served as the 23rd commissioner of the U.S. Food and Drug Administration from 2017 to 2019, and he is a contributor to CNBC and CBS News’ Face the Nation. He is a senior fellow at the American Enterprise Institute, a partner at New Enterprise Associates, and a board member at Pfizer, UnitedHealth Group, and Illumina. He is also an elected member of the National Academy of Medicine and the author of Uncontrolled Spread, a New York Times bestselling book about the COVID-19 pandemic and the national security weaknesses it exposed.